Pfizer
Donghua Yin has extensive experience in oncology clinical pharmacology, having served in various leadership roles at Pfizer from January 2015 to January 2023, including Vice President and Head of Oncology Clinical Pharmacology and Vice President and Head of Clinical Pharmacology for Early Oncology Development. Prior to this, Donghua Yin was a Senior Director in Clinical Pharmacology at Pfizer and worked as a Senior Research Scientist at Pharmacia Corporation from June 2001 to July 2003. Also notable is a postdoctoral role at The Ohio State University and a faculty position at Nanjing Medical University. Donghua Yin holds a Ph.D. in Pharmaceutics from The University of Tennessee Health Science Center and a Master's degree from China Pharmaceutical University.
This person is not in any teams
This person is not in any offices
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.